JFL Life Sciences Ltd
Incorporated in 2010, JFL Life Sciences Limited manufactures pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets & Capsules (B-Lactam) solid oral dosage forms tablets and capsules (general) Solid Oral Dosage forms, and Oral rehydration solutions (ORS).[1]
- Market Cap ₹ 61.2 Cr.
- Current Price ₹ 55.6
- High / Low ₹ 63.8 / 36.0
- Stock P/E 18.5
- Book Value ₹ 32.4
- Dividend Yield 0.00 %
- ROCE 11.8 %
- ROE 10.3 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 7.93% over past five years.
- Tax rate seems low
- Company has high debtors of 176 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 31.78 | 30.17 | 32.77 | 33.59 | 42.83 | 46.55 | |
| 30.45 | 28.31 | 30.61 | 28.23 | 38.90 | 41.99 | |
| Operating Profit | 1.33 | 1.86 | 2.16 | 5.36 | 3.93 | 4.56 |
| OPM % | 4.19% | 6.17% | 6.59% | 15.96% | 9.18% | 9.80% |
| 0.00 | 0.03 | 0.09 | 0.89 | 1.64 | 0.52 | |
| Interest | 0.75 | 1.16 | 1.23 | 2.08 | 1.42 | 0.83 |
| Depreciation | 0.15 | 0.24 | 0.28 | 0.37 | 0.43 | 0.44 |
| Profit before tax | 0.43 | 0.49 | 0.74 | 3.80 | 3.72 | 3.81 |
| Tax % | 27.91% | 28.57% | 27.03% | 26.05% | 24.46% | 13.12% |
| 0.30 | 0.36 | 0.54 | 2.81 | 2.81 | 3.31 | |
| EPS in Rs | 7.08 | 8.49 | 8.74 | 3.50 | 2.55 | 3.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 12% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 62% |
| 3 Years: | 83% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 14% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.50 | 8.02 | 11.00 | 11.00 |
| Reserves | 4.59 | 4.95 | 6.38 | 3.27 | 21.27 | 24.58 |
| 8.41 | 9.33 | 16.82 | 15.85 | 7.18 | 5.69 | |
| 2.73 | 9.63 | 5.31 | 21.12 | 9.61 | 15.37 | |
| Total Liabilities | 16.15 | 24.33 | 29.01 | 48.26 | 49.06 | 56.64 |
| 2.48 | 5.05 | 6.50 | 7.13 | 6.80 | 12.47 | |
| CWIP | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 13.63 | 19.28 | 22.51 | 41.13 | 42.26 | 44.17 | |
| Total Assets | 16.15 | 24.33 | 29.01 | 48.26 | 49.06 | 56.64 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| -3.00 | 3.21 | -5.87 | 2.32 | -9.06 | 8.36 | |
| -0.61 | -2.76 | -1.64 | -0.71 | 0.86 | -6.07 | |
| 3.61 | -0.19 | 7.25 | -1.46 | 8.07 | -2.31 | |
| Net Cash Flow | 0.00 | 0.27 | -0.26 | 0.15 | -0.13 | -0.02 |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 110.95 | 153.16 | 131.54 | 215.15 | 191.41 | |
| Inventory Days | 21.43 | 51.75 | 72.47 | 211.64 | 133.99 | |
| Days Payable | 17.79 | 121.71 | 57.70 | 218.43 | 77.85 | |
| Cash Conversion Cycle | 114.58 | 83.20 | 146.31 | 208.36 | 247.55 | |
| Working Capital Days | 125.65 | 103.80 | 170.30 | 197.44 | 269.64 | |
| ROCE % | 11.74% | 10.26% | 23.13% | 15.44% |
Documents
Announcements
-
Board Meeting Intimation
26 July 2024 - JFL LIFE SCIENCES LIMITED has informed about Board Meeting to be held on 02-Aug-2024 to consider and approve Increase in authorised capital/Bonus/Fund raising/Dividend.
-
Reply to Clarification- Financial results
22 July 2024 - Exchange had sought clarification from Jfl Life Sciences Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. …
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
15 July 2024 - Jfl Life Sciences Limited has informed about Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Updates
15 July 2024 - Jfl Life Sciences Limited has informed regarding 'Non-applicability of Corporate Governance Provisions as per SEBI (LODR) Regulation, 2015'.
-
Updates
8 July 2024 - Jfl Life Sciences Limited has informed regarding 'Intimation of product launch under Regulation 30 of SEBI Listing Regulations'.
Certified Pharma Manufacturer[1] JFL is a WHO–GMP certified pharmaceutical company with 320 products. Its business is organized into following product categories:
Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet and capsules (General), Oral Rehydration Solutions (ORFL)